May 2004 (Part I)
Enrollment Underway in First Drug-eluting Coronary Stent Registry Assessing Impact of Stent-Deployment Technique on Patient Outcomes eCYPHERSM S.T.L.L.R. Registry to Include 1,500 patients at 50 U.S. Treatment Centers Patient enrollment is underway in the eCYPHERSM S.T.L.L.R.* Registry, the first study specifically designed to evaluate the impact of stent-deployment technique on patient outcomes achieved with the Cypher® Sirolimus-eluting Coronary Stent. Everolimus Eluting Coronary Stent ...
|
CME Offering: The Impact of Sirolimus-Eluting Stents on Patients at High Risk for Restenosis with Bare Metal Stenting
This review focuses on the impact of sirolimus-eluting stent placement in patients and lesions with traditionally high rates of restenosis with bare metal stenting: patients with diabetes mellitus, small coronary vessels, and long lesions. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. Analysis of 1-year clinical outcomes in the SIRIUS trial : a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high ...
|
Clinical & Industry News
Drug-Eluting Coronary Stent Abbott Vascular Devices, a division of Abbott Laboratories, announced the enrollment of the first patient in the ZOMAXX I drug-eluting coronary stent clinical trial. The ZoMaxx stent used in this study consists of three key components: the drug, the stent platform and the polymer carrier. Coronary Stent, which is currently under CE Mark review as a non-drug eluting stent.
|
Clinical and Industry News
The PASSION trial showed that in AMI patients, the Taxus stent achieved reductions in cardiac death (3.9 percent for the Taxus stent versus 6.2 percent for the bare-metal control), target lesion revascularization (5.3 percent for the Taxus stent versus 7.8 percent for bare metal) and reinfarction (1.7 percent for the Taxus stent versus 2.0 percent for bare metal). s Xience V? Drug-Eluting Coronary Stent Superior To Taxus® Stent in SPIRIT II Clinical Trial Positive six-month results of Abbott...
|
Clinical and Industry News I
INSIDE: Boston Scientific Announces European Launch of Its TAXUS Paclitaxel-Eluting Stent System; St. Jude Medical Plans Mid-year Global Launch of Next-Generation Angio-Seal Vascular Closure Device; St. Jude Medical Receives CE Marking for Single-Coil Defibrillation Lead; Free White Paper: An Evidence-Based Approach to Managing the Cath Lab: Delivering Stellar Patient Outcomes, Customer Satisfaction, and Financial Success in the Era of Drug-Eluting Stents; FDA Clears New Test That Helps Physicians Determine Whether Aspirin is Working in Patients to Prevent Heart Attack and Stroke; Medtronic Announces Start of Clinical Trial to Evaluate Its Exponent Self-Expanding Carotid Stent System;Medtronic Announces European Launch of New Driver Coronary Stent Using Modular Technology and Cobalt-based Alloy; Siemens Provides Monitoring Solution to New Heart Hospital; Cleveland Clinic?s Dr. Yadav Named in AHA Top 10 Research 2002; UIC Cardiologists Use 3-D Imaging To Help Repair Congenital Defects; St. Jude Medical Announces FDA Approval of New Labeling For 6F Angio-Seal STS Platform; Merit Medical Introduces New Safety Procedural Kit for Vascular Access; Study Shows Lower Risk of Impairment of Renal Function Using Visipaque?; Doctors Probe Miscarriage Link to Heart Risk
|
Research Update: Original Research Abstracts from The Journal of Invasive Cardiology, October 2005 ? December 2005
METHODS: Thirty patients undergoing transradial coronary intervention (Group A: 15 de novo procedures, Group B: 15 previous transradial procedures) underwent radial artery intravascular ultrasound (IVUS) before catheter insertion. We sought to investigate whether abciximab can reduce in-stent restenosis after coronary stenting in diabetic patients. CONCLUSION: Abciximab does not reduce angiographic restenosis or TLR in type 2 diabetic patients undergoing nonurgent coronary stenting.
|
CME/CEU OFFERING: Sirolimus-Eluting Stents: A Leap Forward in the Prevention of Restenosis After Percutaneous Coronary Intervention
The following activity is supported by an unrestricted educational grant from Cordis Corporation.
|
Selected News from the American College of Cardiology Annual Scientific Sessions: March 24-27, 2007, New Orleans, Louisiana
The American College of Cardiology (www.acc.org) represents the majority of board-certified cardiovascular physicians in the United States. Its mission is to advocate for quality cardiovascular care through education, research, promotion, development and application of standards and guidelines, and to influence health care policy.
|
News from the American College of Cardiology Annual Scientific Session 2005
Held March 6-9, 2005, Orlando, Florida
|
News from the 55th Annual Scientific Session of the American College of Cardiology Meeting
Drug-Eluting Coronary Stent Abbott announced the first clinical results for its investigational ZoMaxx? ? Key findings presented by Dr. Cohen at the ACC meeting include: ?
|
